A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects

AIMS: We investigated the relative pharmacokinetics, pharmacodynamics, and safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab following injection at three different sites. METHODS: Sixty healthy subjects (39 male, 21 female; age 20–45 years) were randomized to r...

Descripción completa

Detalles Bibliográficos
Autores principales: Lunven, Catherine, Paehler, Tobias, Poitiers, Franck, Brunet, Aurélie, Rey, Jacques, Hanotin, Corinne, Sasiela, William J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262094/
https://www.ncbi.nlm.nih.gov/pubmed/25256660
http://dx.doi.org/10.1111/1755-5922.12093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262094/
https://www.ncbi.nlm.nih.gov/pubmed/25256660
http://dx.doi.org/10.1111/1755-5922.12093

Ejemplares similares